Samsung Bioepis’s Biosimilar Trastuzumab First To Take On Roche’s Herceptin In EU
Executive Summary
Samsung Bioepis’s Ontruzant is likely to be the first biosimilar to take on Roche’s Herceptin in the EU market after it was recommended for marketing authorization by the EMA’s CHMP on Sept 15.